{"id":"hrs-5965","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL5432020","moleculeType":null,"molecularWeight":"1336.59"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, HRS-5965 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"HRS-5965 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:26.873Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06674915","phase":"PHASE1","title":"Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HRS-5965 in Subjects With Hepatic Impairment","status":"COMPLETED","sponsor":"Chengdu Suncadia Medicine Co., Ltd.","startDate":"2024-11-26","conditions":"Complement Mediated Primary or Secondary Glomerular Diseases","enrollment":24},{"nctId":"NCT06715943","phase":"PHASE3","title":"Efficacy and Safety of HRS-5965 in Patients With PNH Who Are Still Anemia After Anti-C5 Antibody Treatment","status":"COMPLETED","sponsor":"Chengdu Suncadia Medicine Co., Ltd.","startDate":"2025-01-07","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":39},{"nctId":"NCT06490991","phase":"PHASE1","title":"Comparison of HRS-5965 Capsules and Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"Chengdu Suncadia Medicine Co., Ltd.","startDate":"2024-07-17","conditions":"Paroxysmal Nocturnal Hemoglobinuria，IgA Nephropathy","enrollment":16},{"nctId":"NCT06238544","phase":"PHASE2","title":"Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chengdu Suncadia Medicine Co., Ltd.","startDate":"2024-02-06","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":132},{"nctId":"NCT06593938","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy","status":"COMPLETED","sponsor":"Chengdu Suncadia Medicine Co., Ltd.","startDate":"2024-10-25","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":76},{"nctId":"NCT07035665","phase":"PHASE1","title":"A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy Subjects","status":"COMPLETED","sponsor":"Chengdu Suncadia Medicine Co., Ltd.","startDate":"2025-06-30","conditions":"IgA Nephropathy, Paroxysmal Nocturnal Hemoglobinuria","enrollment":16},{"nctId":"NCT07040787","phase":"PHASE1","title":"Investigation of Drug-drug Interaction of HRS-5965 With Clopidogrel and Clarithromycin in Healthy Subjects","status":"COMPLETED","sponsor":"Chengdu Suncadia Medicine Co., Ltd.","startDate":"2025-07-08","conditions":"Complement Mediated Glomerular Diseases, Hemolytic Anemia","enrollment":36},{"nctId":"NCT07014826","phase":"PHASE3","title":"A Trial of HRS-5965 Capsule in Primary IgA Nephropathy","status":"RECRUITING","sponsor":"Chengdu Suncadia Medicine Co., Ltd.","startDate":"2025-06-04","conditions":"Primary IgA Nephropathy","enrollment":378},{"nctId":"NCT06684041","phase":"PHASE1","title":"A Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Study, and QT Interval Study of HRS-5965 Capsules in Healthy Subjects","status":"COMPLETED","sponsor":"Chengdu Suncadia Medicine Co., Ltd.","startDate":"2024-11-09","conditions":"Hemolytic Anemia","enrollment":32},{"nctId":"NCT06137768","phase":"PHASE2","title":"A Trial of HRS-5965 Tablets in Primary IgA Nephropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chengdu Suncadia Medicine Co., Ltd.","startDate":"2023-12-19","conditions":"Primary IgA Nephropathy","enrollment":123},{"nctId":"NCT05505955","phase":"PHASE1","title":"Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency","status":"COMPLETED","sponsor":"Chengdu Suncadia Medicine Co., Ltd.","startDate":"2022-10-08","conditions":"Glomerulonephritis","enrollment":83},{"nctId":"NCT06051357","phase":"PHASE2","title":"Proof of Concept Study to Assess the Efficacy, Safety of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria","status":"COMPLETED","sponsor":"Chengdu Suncadia Medicine Co., Ltd.","startDate":"2023-11-15","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":26},{"nctId":"NCT06567392","phase":"PHASE1","title":"A Study to Evaluate the Mass Balance of [14C] HRS-5965 in Healthy Adult Male Volunteers","status":"COMPLETED","sponsor":"Chengdu Suncadia Medicine Co., Ltd.","startDate":"2024-09-03","conditions":"Complement Mediated Primary or Secondary Glomerular Diseases","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HRS-5965","genericName":"HRS-5965","companyName":"Chengdu Suncadia Medicine Co., Ltd.","companyId":"chengdu-suncadia-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HRS-5965 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}